Gland Pharma signs pact with Neuland Labs

Hyderabad: Gland Pharma Limited and Neuland Laboratories Limited announced a long-term strategic CDMO partnership. Under the partnership Gland will establish a sterile manufacturing suite for Active Pharmaceutical Ingredients (APIs) pertaining to microparticle depot products.

Srinivas Sadu, Executive Chairman, Gland Pharma Limited, said: “ By leveraging the complementary strengths of both organizations, we will provide a robust and scalable CDMO solution backed by world-class quality, compliance and manufacturing excellence. We believe this partnership creates a strong foundation for sustainable growth and long-term value creation for our customers and both organizations.”

Saharsh Davuluri, CEO, Neuland Laboratories, said: “Through this partnership with Gland Pharma, we are combining Neuland’s expertise in complex APIs with Gland’s proven sterile manufacturing capabilities to create a differentiated platform for global customers. Together, we are strengthening our ability to deliver the quality, reliability, and supply assurance that innovators and generic companies expect from their CDMO partners.”

The collaboration combines Neuland’s Complex API development and manufacturing capabilitie with Gland Pharma’s global sterile manufacturing expertise and strong regulatory compliance track record, to serve growing worldwide demand for sterile APIs.